ELARA trial: tisagenlecleucel response extends to 4 years in follicular lymphoma
Researchers presented 4-year follow-up data from the phase 2 ELARA study, showing that response to tisagenlecleucel continues to deepen in patients with follicular
18-IMCL
News
ASCO 2025
Video Interviews
What do the real-world data show on luspatercept in LR-MDS?
In this video interview with Idoroenyi Amanam, MD, an assistant professor in City of Hope’s Division of Leukemia in the Department of Hematology
18-IMCL
News
GOLSEEK-1 phase 3 study of golcadomide for untreated LBCL
Golcadomide, an investigational first-in-class oral CELMoD, is being assessed in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients with high-risk
EHA 2025
B-ALL patients refractory to brexu-cel face poor survival outcomes
Relapse after treatment with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) is associated with limited survival outcomes, “underscoring a need
EHA 2025
Pediatric-inspired Ph– ALL protocol reduces toxicity without improving survival
Researchers introduced a pediatric-inspired treatment protocol at their institution for patients with Philadelphia-negative (Ph–) acute lymphoblastic leukemia (ALL) and found that overall survival
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves tafasitamab combo therapy for relapsed or refractory follicular lymphoma
The US Food and Drug Administration (FDA) has approved tafasitamab-cxix, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide
EHA 2025
Post-CAR-T recovery of T cell, NK cell counts predicts long-term prognosis in B-ALL
Early recovery of specific T-cell counts and natural killer (NK) cell counts after CD19 chimeric antigen receptor (CAR)-T therapy can be used as
News
Study finds ropeginterferon alfa-2b is ‘superior’ 2nd-line treatment for essential thrombocythemia
A study compared second-line treatment options for essential thrombocythemia (ET) and found that ropeginterferon alfa-2b “outperformed” anagrelide in both efficacy and safety outcomes.
EHA 2025
Longer-term follow-up demonstrates efficacy of nemtabrutinib for refractory FL
Follow-up results from the BELLWAVE-003 study assessing nemtabrutinib in patients with hematologic malignancies showed continued antitumor activity and no new safety concerns with
EHA 2025
Meetings / Conferences
Myeloproliferative Neoplasms
Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’
Andrew Kuykendall, MD, SOHO Insider MPN podcast host, and assistant professor in the Department of Malignant Hematology at Moffitt Cancer Center, delivers live